The impact of hormone replacement therapy on metabolic syndrome components in perimenopausal women

Medical Hypotheses

Volumn 74, Issue 1, 2010, Pages 162-163

  Korljan, Betty ^a   Bagatin, Jugoslav ^a   Kokić, Slaven ^a   Berović Matulić, Nina ^a   Baršić Ostojić, Sanja ^b   Deković, Ana ^c  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b University Hospital Sveti Duh   (Croatia)

^c Private Psychiatric Practice   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTROGEN; GESTAGEN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; COHORT ANALYSIS; GLUCOSE INTOLERANCE; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASOMOTOR DISORDER;

CARDIOVASCULAR DISEASES; COHORT STUDIES; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PERIMENOPAUSE; RESEARCH DESIGN; RISK; WOMEN'S HEALTH;

EID: 70450231646     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.07.008     Document Type: Article

References (21)

1. Collins P., Rosano G., Casey C., et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 28 (2007) 2028-2040
2. Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421.
3. Alberti K.G., Zimmet P., and Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23 (2006) 469-480
4. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
5. Didangelos T.P., Thanopoulou A.K., Bousboulas S.H., et al. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 20 (2004) 1393-1401
6. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33.
7. Gompel A., Barlow D., Rozenberg S., et al. Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses' Health Study. Maturitas 55 (2006) 1-4
8. Cobin R.H., Futterweit W., Ginzburg S.B., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 12 (2006) 315-337
9. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007) 1465-1477
10. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 15 (2006) 35-44
11. Manson J.E., Rimm E.B., Colditz G.A., et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 2 (1992) 665-673
12. Margolis K.L., Bonds D.E., Rodabough R.J., et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative hormone trial. Diabetologia 47 (2004) 1175-1187
13. Green J.S., Stanforth P.R., Rankinen T., et al. The effects of exercise training on abdominal visceral fat, body composition, and indicators of the metabolic syndrome in postmenopausal women with and without estrogen replacement therapy: the HERITAGE family study. Metabolism 53 (2004) 1192-1196
14. Greenfield J.R., Samaras K., Jenkins A.B., et al. Moderate alcohol consumption, estrogen replacement therapy, and physical activity are associated with increased insulin sensitivity: is abdominal adiposity the mediator?. Diabet Care 26 (2003) 2734-2740
15. Shakir Y.A., Samsioe G., Nerbrand C., et al. Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: women's health in the Lund area study. Menopause 11 (2004) 549-555
16. Kuh D., Langenberg C., Hardy R., et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 112 (2005) 476-485
17. Ko H.S., Kim C.J., and Ryu W.S. Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women. Korean J Intern Med 20 (2005) 33-39
18. Palin S.L., Kumar S., Sturdee D.W., et al. Hormone replacement therapy for postmenopausal women with diabetes. Diabet Obes Metab 3 (2001) 187-193
19. Salpeter S.R., Walsh J.M., Ormiston T.M., et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabet Obes Metab 8 (2006) 538-554
20. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
21. Gambacciani M., Ciaponi M., Cappagli B., et al. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. Maturitas 39 (2001) 125-132